[Kidney function and bacteriological and histological research in the therapy of experimental E. coli pyelonephritis using trimethoprim-sulfamethoxazole (TMP-SMO)].
40 uninephrectomized male Wistar rats with an experimental E.-coli-022-pyelonephritis (PN) were treated twice daily for 9 days with 30 mg trimethoprim and 150 mg sulfamethoxazole (TMP-SMO) i.p. Bacteriologically most of the kidneys became sterile. Histologically a significant reduction of the frequency of severe PN was found in the treated group. The biologic half-life of 131I-hippuran indicated a decrease of excretory function which was reversible. Urine osmolality and osmotic clearance were increased after oral water loading in 10 untreated control animals with PN but not in the treated group. The 9 day treatment had a favourable effect bacteriologically, histologically and also on renal function.
D000818:Animals; D004338:Drug Combinations / Q000627:therapeutic use; D004353:Drug Evaluation, Preclinical; D004927:Escherichia coli Infections / Q000188:drug therapy* / Q000382:microbiology / Q000503:physiopathology; D006207:Half-Life; D007465:Iodohippuric Acid; D007668:Kidney / Q000382:microbiology / Q000503:physiopathology*; D008297:Male; D009392:Nephrectomy; D011704:Pyelonephritis / Q000188:drug therapy* / Q000382:microbiology / Q000503:physiopathology; D051381:Rats; D011919:Rats, Inbred Strains; D013420:Sulfamethoxazole / Q000627:therapeutic use*; D013997:Time Factors; D014295:Trimethoprim / Q000627:therapeutic use*; D015662:Trimethoprim, Sulfamethoxazole Drug Combination
D004338:Drug Combinations; D007465:Iodohippuric Acid; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D014295:Trimethoprim; D013420:Sulfamethoxazole
Nierenfunktion, bakteriologische und histologische Untersuchungen bei Therapie der experimentellen E.-coli-Pyelonephritis mit Trimethoprim-Sulfamethoxazol (TMP-SMO).